Bristol Myers' immunotherapy can now be used before and after surgery in the U.S. Elsewhere, J&J, Bayer, Bristol Myers Squibb and Pfizer are trimming staff.

Having already been on a winding journey, Enjaymo, which Sanofi acquired through a 2018 buyout of Bioverativ, is now headed to Recordati as part of a deal announced Friday.

The agency will offer earlier meetings with drugmakers as well as solicit more patient feedback on the process.

Today, a brief rundown of news from Metsera and Novartis, as well as updates from Sanofi and Wave Life Sciences that you may have missed.

The company will permit six generic drugmakers to make and sell lenacapavir in 120 countries that have high incidence of the disease, but limited resources.

Paris, France – October 1st, 2024 - AzurBio Pharma, specializing in bringing innovative pharmaceutical products to European markets and focusing on rare and serious diseases with unmet medical needs, ...

The latest investment in the Lebanon site comes after an announcement in May of $5.3 billion earmarked to build production capacity for Lilly’s obesity and diabetes drugs. All told, the company said ...

The biotech, which has now raised more than $200 million since launch, is advancing an eczema treatment that could start human trials next year.

It’s the first time, according to the insurer, that this type of model has been used to bring a Humira biosimilar to market, and it yields a much lower cost than both the brand-name version of the ...